# VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD)

> **NCT00727753** · — · COMPLETED · sponsor: **University of Zurich** · enrollment: 54 (actual)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** Ranibizumab
- **DRUG:** Bevacizumab
- **OTHER:** No treatment

## Key facts

- **NCT ID:** NCT00727753
- **Lead sponsor:** University of Zurich
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2012-12
- **Final completion:** 2013-10
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2015-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00727753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00727753, "VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00727753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*